We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PhRMA: PENALTIES NEEDED FOR GENERICS THAT MISS DEADLINES
PhRMA: PENALTIES NEEDED FOR GENERICS THAT MISS DEADLINES
May 14, 2004
The FDA should implement an administrative penalty to discourage generic drug firms from missing deadlines for submitting notifications that start the 45-day clock for drugmakers to file patent-infringement lawsuits, PhRMA said in comments suggesting changes in FDA drug patent rules.